Literature DB >> 7645967

Inhibitory effect of caffeine on potentially lethal damage repair in cisplatin-treated human osteosarcoma cells.

H Yasutake1, H Tsuchiya, K Tomita, T Matsunaga, O Nikaido, T Mori.   

Abstract

Human osteosarcoma cells, that were cultured to confluence and maintained under low nutrient conditions, showed potentially lethal damage repair after cisplatin treatment. This repair was inhibited by a non-toxic dose of caffeine. Flow cytometric analysis indicated that cisplatin-treated cells accumulated in the S phase by 24 hr, followed by accumulation in the G2/M phase. Caffeine inhibited the initial accumulation in the S phase and the release of cells from the G2/M block. DNA synthesis was also inhibited by the cisplatin treatment. The addition of caffeine significantly reversed this inhibition. The content of DNA-bound platinum decreased over time after cisplatin treatment. Caffeine did not influence platinum content, nor did it directly affect the DNA excision repair. Cisplatin inhibits DNA synthesis in the S phase, but caffeine reduces this inhibition. Caffeine-treated cells that pass through S phase are incapable of recovery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645967

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases.

Authors:  Michiaki Karita; Hiroyuki Tsuchiya; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Hideji Nishida
Journal:  Int J Clin Oncol       Date:  2011-11-01       Impact factor: 3.402

2.  In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells.

Authors:  H Ogasawara; K Nishio; T Ishida; H Arioka; K Fukuoka; N Saijo
Journal:  Jpn J Cancer Res       Date:  1997-11

Review 3.  Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review.

Authors:  Sunjeev S Phull; Alireza Rahimnejad Yazdi; Michelle Ghert; Mark R Towler
Journal:  J Bone Oncol       Date:  2020-12-16       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.